Michael Joseph Rybak

Michael Joseph Rybak




Office location

EACPHS, Room 4148


Pharmacy Practice


Professor, Department of Pharmacy Practice
Director, Anti-Infective Research Laboratory

Degrees and Certifications

M.P.H. Wayne State University, School of Medicine, Detroit 1998-2005,
Pharm.D. Wayne State University, Detroit 1979-1981 Pharmacy
B.S. Northeastern University, Boston 1976-1979 Pharmacy
State University College of Buffalo, Buffalo 1975-1976 Biology
Associates Erie Community College, Amherst 1973-1975 Science

Added Qualification for Infectious Disease Pharmacotherapy, 3/00
American Pharmaceutical Association
Board Certified Pharmacotherapy Specialist - 1992
Board of Pharmaceutical Specialties

Positions and Employment

10/03 Present Associate Dean Of Research, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University
4/02 Present Director, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy & Health Sciences
8/95 Present Professor of Medicine (Adjunct), Division of Infectious Diseases, Wayne State University
7/93 7/03 Director of Research & Education, Department of Pharmacy, Detroit Receiving Hospital & University Health Ctr.
5/93 Present Professor of Pharmacy Practice, Wayne State University School of Pharmacy
6/90 4/02 Director, Anti-Infective Research Laboratory, Detroit Receiving Hospital & University Health Center
8/88 8/95 Associate Professor of Medicine (Adjunct), Division of Infectious Diseases, Wayne State University
5/87 5/93 Associate Professor of Pharmacy Practice, Wayne State University
7/85 Present Director, Research Fellowship Program in Infectious Diseases Pharmacotherapy, Wayne State University
7/81 5/87 Assistant Professor of Pharmacy Practice, Wayne State University
Editor: Scientific Field Editor:  Infectious Diseases: Pharmacotherapy, 8/02 - Present 
 Scientific Editor: Infectious Diseases:  Pharmacotherapy, 6/00 - Present
Chairman: Editorial Panel: Infectious Diseases: Annals of Pharmacotherapy, 1991-95
Editorial Panel: Infectious Diseases: American Journal of Health System Pharmacists, 1994-98
Editorial Panel: Infectious Diseases: Pharmacotherapy, 3/95 6/00
Editorial Panel: Infectious Diseases: Antimicrobial Agents and Chemotherapy, 1/97 1999, 2000-2002  
Editorial Panel: Infectious Disease Pharmacotherapy, 7/98 Present
Reviewer:  Clinical Infectious Diseases
  Antimicrobial Agents Chemotherapy
  Journal Antimicrobial Chemotherapy

Awards and Honors

  • Preceptor for Fellowships in Infectious Diseases Pharmacotherapy: 1985-87 (Lisa Albrecht, Pharm.D.), 1989-91 (Elaine Bailey, Pharm.D.*), 1990-92 (Kenneth Lamp, Pharm.D.), 1991-93 (Betty McGrath, Pharm.D.), 1992-94 (S. Lena Kang, Pharm.D.), 1993-95 (Shirley Palmer, Pharm.D.** and Diane Cappelletty, Pharm.D.), 1995-97 (Renee-Claude Mercier, Pharm.D. and Heather Houlihan, Pharm.D.), 1996-97 (Daniella Stokes, M.D.), 1996-98 (Jeffrey Aeschlimann, Pharm.D.), 1997-99 (Ellie Hershberger, Pharm.D.), 1998-2000 (Elizabeth Coyle, Pharm.D. and Ronda Akins, Pharm.D.), 1999-2001(George Allen, Pharm.D.***), 2000-2002 (Raymond Cha, Pharm.D.), 2002-2004 (Vanthida Huang�, Pharm.D., Kerry Tedesco, Pharm.D.,), 2003-2005 (Kimberly Leuthner, Pharm.D., Brian Tsuji, Pharm.D.), 2005-2007 (Warren Rose, Pharm.D., Judy Chin, Pharm.D.), 2006-2008 (Steve Leonard, Pharm.D., Romal Bhan, M.D.)
  • * ACCP-Miles Infectious Diseases Fellowship Award, 1989
  • ** ACCP-Ortho-McNeil Infectious Diseases Fellowship Award, 1994
  • *** ACCP-Ortho-McNeil Infectious Diseases Fellowship Award, 2000
  •  ACCP-Merck Infectios Diseases Fellowship Award, 2003
  • ACCP-Ortho-McNeil Infectious Diseases Fellowship Award, 2007
  • American Society of Health-System Pharmacists, Award for Sustained Literature Contributions to the Pharmacy
  • Literature for ASHP, 2002
  • Impact paper in ID Pharmacists Research Award, SIDP 9/00
  • Distinguished Faculty Fellowship Award, Wayne State University, 4/97
  • Fellow, Infectious Disease Society of America, 9/96
  • Wayne State University Career Chair Development Award, 1992
  • R.W. Johnson Research Institute Fellowship Award, 1992
  • Wayne State University Academic Achievement Award for Natural Sciences, 1991
  • American College of Clinical Pharmacy Fellow Recognition Award, 1991
  • Merck Foundation Fellowship Award, 1990
  • The Upjohn Pharmacy Research Award - Michigan Society of Hospital Pharmacists, 1990

Primary Research Interest

Leuthner KD, Cheung CM, Rybak MJ. Effect of Protein Binding on TD-6424 and THRX-932864, two New Glycopeptides, against 50 Glycopeptide Non-Susceptible Staphylococci including Vancomycin-Resistant Staphylococcus aureus (VRSA) compared to vancomycin, quinupristin/dalfoprisitin, linezolid and daptomycin. Theravance

Recent Publications

  1. Rybak MJ, LaPlante KL. Community-Associated Methicillin-Resistant Staphylococcus aureus: A Review. In: Reviews of Therapeutics. Pharmacotherapy 2005;25(1):74-85.
  2. Huang V, Rybak MJ. Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. In: Antimicrobial Agents and Chemotherapy. 2005;49(1):302-308.
  3. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an invitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2005;2735-2745.
  4. Rybak MJ, Cha R, Cheung CM, Meka VG, Kaatz GW. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diag Microbiol Infect Dis. 2005;51:119-125.
  5. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest. 2005 Sep;128(3):1414-22.
  6. Huang V, Rybak MJ. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.J Antimicrob Chemother. 2006 Jan;57(1):116-21.
  7. Brown SD,Rybak MJ. Antimicrobial Susceptibility Among Respiratory Tract Pathogens From the Northern States of the USA. Infect Dis Clin Pract 2005; 13: 179-186
  8. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbial Infect 2006;12:24-32
  9. Leuthner KD, Cheung CM, Rybak MJ. Pulsatile Delivery of Clarithromycin Alone or in Combination with Amoxicillin against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006; 813-816.
  10. LaPlante, KL, Rybak MJ, Leuthner KD, Cheung CM, Chin JN. Impact of Enterococcus faecalis on the Bactericidal Activities of Arbekacin, Daptomycin, Linezolid, and Tigecycline against Methicillin-Resistant Staphylococcus aureus in a Mixed-Pathogen Pharmacodynamic Model Antimicrob Agents Chemother. 2006;50:12981303.
  11. Rybak MJ. Pharmacodynamics: Relation to Antimicrobial Resistance. Am.J. Med. 2006;Vol 119:37-44.
  12. Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.Diagn Microbiol Infect Dis. 2006 Jan;54(1):73-7.
  13. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin.Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.
  14. Rybak MJ. Pharmacodynamics: Relation to Antimicrobial Resistance.American Journal of Infection Control 2006;Vol 34:38-45
  15. Rybak MJ, Rose, W. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110.
  16. Leuthner KD, Cheung CM, Rybak MJ.Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006 Aug;58(2):338-43.
  17. Davis SL, Rybak MJ, Muhammad A, McKinnon Peggy S ,Kaatz GW. Characteristics of Patients With Healthcare-Associated Infection Due to SCCmec Type IV Methicillin-Resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2006 Oct;27(10):1025-31.
  18. Kerns RJ, Rybak MJ, Cheung CM. Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria.Diagn Microbiol Infect Dis. 2006 Apr;54(4):305-10
  19. Tsuji BT, Rybak MJ, Sakoulas G, Lau KL.Evaluation of Accessory Gene Regulator (agr) Group and Function in the Proclivity Towards Vancomycin Intermediate Resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Antimicrob Agents Chemother. 2007 Mar;51(3):1089-91.
  20. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial Activity of Ceragenins against Clinical Isolates of Resistant Staphylococcus aureus. Antimicrob Agents Chemother. Antimicrob Agents Chemother. 2007;51:1268-73
  21. Tsuji BT, Rybak MJ, Cheung CM, Amjad M, Kaatz GW.Community-and health care-associated methicillin resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis. 2007; 58:41-47
  22. LaPlante KL, Rybak MJ, Amjad M, Kaatz GW .Clindamycin Resistance and SCCmec Type in Community- and Hospital-Associated Methicillin Resistant Staphylococcus aureus Clindamycin Resistance and Staphylococcus aureus. Pharmacotherapy. 2007
  23. Laplante KL, Rybak MJ, Amjad M, Kaatz GW. Antimicrobial Susceptibility and
  24. Staphylococcal Chromosomal Cassette mecType in Community-and Hospital-Associated Methicillin-Resistant Staphylococcus aureus. Pharmacotherapy. 2007 Jan;27(1):3-10.
  25. Rose W,Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas G.Correlation of Vancomycin and Daptomycin Susceptibility in Staphylococcus aureus in reference to Accessory Gene Regulator (agr) Polymorphism and Function. J Antimicrob Chemother 2007; 60(2):334-40.
  26. Laplante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW. Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob Agents Chemother.2007; Apr;51(4):1315-20.
  27. Rose W,Rybak MJ, Kaatz GW.Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.J Antimicrob Chemother. 2007;Aug;60(2):334-40.
  28. Lodise T, Mckinnon P, Levine D Rybak MJ,. Impact of Empirical Therapy Selection on Outcomes of Intravenous Drug Users with Methicillin Susceptible Staphylococcus aureus Infective Endocarditis. Antimicrob Agents Chemother. 2007 Oct;51(10):3731-3
  29. Maki DG, Ebert SC, Rybak MJ. Antimicrobial Stewardship:Case study and panel discussion. Pharmacotherapy. 2007 Oct;27:136S-143S
  30. Rybak MJ .Antimicrobial Stewardship: Pharmacotherapy. 2007 Oct;27:131S-135S.
  31. Sakoulas G. Rose W, Rybak MJ, Pillai S, Alder J, Moellering R C Jr, Eliopoulos GM. Evaluation of Methicillin-Susceptible Staphylococcus aureus Endocarditis Developing Nonsusceptibility to Daptomycin. J Clin Microbiol. 2007 Advanced Access published Nov 14
  32. Golstein EJ, Citron DM, Warren YA, Tyrrell K, and Rybak MJ. Virulence characteristics of community acquired Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-acquired and hospital acquired methicillin-resistant and susceptible Staphylococcus aureus. J Med Microbiol. Pending Publication 11/29/2007
  33. Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, Rybak MJ.Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes.Pharmacotherapy. 2007 Dec;27(12):1611-8.
  34. Chin JN, Jones RJ, Helio SS, Savage PB, and Rybak MJ.Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother Advanced Access published 12/07

Research website


Laboratory Web Site


Return to profile list